A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma

Trial Profile

A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs ONO 7268MX2 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 20 Jan 2018 Results assessing tolerability of ONO-7268MX2 presented at the 2018 Gastrointestinal Cancers Symposium
    • 13 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top